From: Epigenetic modulators as therapeutic targets in prostate cancer
Drug | Comercial name | Company | Class | Year of approval | Treatment type | Cancer |
---|---|---|---|---|---|---|
5-Azacytidine | Vidaza® | Celgene Corporation | DNMTi | 2004 | Single agent | Myelodysplastic syndrome |
5-Aza-2′-deoxycytidine | Dacogen® | Eisai | DNMTi | 2006 | Single agent | Myelodysplastic syndrome |
Vorinostat/SAHA | Zolinza® | Merck | Pan-HDACi | 2006 | Single agent | Cutaneous T cell lymphoma |
Romidepsin | Istodax® | Celgene Corporation | Class I HDACi | 2009 | Single agent | Cutaneous and peripheral T cell lymphoma |
Belinostat | Beleodaq® | Spectrum Pharmaceuticals, Inc. | Pan-HDACi | 2014 | Single agent | Peripheral T cell lymphoma |
Panobinostat | Farydak® | Novartis | Pan-HDACi | 2015 | Combination with bortezomid and examethasone | Multiple myeloma |